- Home
- AMLX vs TERN Comparison
AMLX vs TERN Comparison
Compare AMLX & TERN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AMLX
- TERN
- Stock Information
- Founded
- AMLX 2014
- TERN 2017
- Country
- AMLX United States
- TERN United States
- Employees
- AMLX N/A
- TERN N/A
- Industry
- AMLX Biotechnology: Pharmaceutical Preparations
- TERN Biotechnology: Pharmaceutical Preparations
- Sector
- AMLX Health Care
- TERN Health Care
- Exchange
- AMLX Nasdaq
- TERN Nasdaq
- Market Cap
- AMLX 749.9M
- TERN 634.5M
- IPO Year
- AMLX 2022
- TERN 2021
- Fundamental
- Price
- AMLX $10.20
- TERN $7.22
- Analyst Decision
- AMLX Strong Buy
- TERN Buy
- Analyst Count
- AMLX 7
- TERN 6
- Target Price
- AMLX $12.29
- TERN $13.99
- AVG Volume (30 Days)
- AMLX 1.3M
- TERN 1.1M
- Earning Date
- AMLX 08-07-2025
- TERN 08-05-2025
- Dividend Yield
- AMLX N/A
- TERN N/A
- EPS Growth
- AMLX N/A
- TERN N/A
- EPS
- AMLX N/A
- TERN N/A
- Revenue
- AMLX N/A
- TERN N/A
- Revenue This Year
- AMLX N/A
- TERN N/A
- Revenue Next Year
- AMLX N/A
- TERN N/A
- P/E Ratio
- AMLX N/A
- TERN N/A
- Revenue Growth
- AMLX N/A
- TERN N/A
- 52 Week Low
- AMLX $2.09
- TERN $1.87
- 52 Week High
- AMLX $10.20
- TERN $11.40
- Technical
- Relative Strength Index (RSI)
- AMLX 69.71
- TERN 59.36
- Support Level
- AMLX $9.15
- TERN $6.78
- Resistance Level
- AMLX $10.06
- TERN $7.78
- Average True Range (ATR)
- AMLX 0.54
- TERN 0.49
- MACD
- AMLX 0.12
- TERN -0.02
- Stochastic Oscillator
- AMLX 98.53
- TERN 63.82
About AMLX Amylyx Pharmaceuticals Inc.
Amylyx Pharmaceuticals Inc is a clinical-stage pharmaceutical company working on developing a novel therapeutic for amyotrophic lateral sclerosis and other neurodegenerative diseases. It has one operating segment which is the business of researching and developing therapeutics for neurodegenerative disorder and endocrine conditions.
About TERN Terns Pharmaceuticals Inc.
Terns Pharmaceuticals Inc is a clinical-stage biopharmaceutical company. The company is developing a portfolio of small-molecule single-agent and combination therapy candidates for the treatment of non-alcoholic steatohepatitis, NASH, and other chronic liver diseases. Its product candidates include TERN-701, TERN-601, TERN-501 and TERN-800.